Speciality
Spotlight

 




 


Oncology


 

 





Malignant

   

  • Kirita T, Ohgi K, Shimooka H, et al [ Nara Med Univ, Japan]

    Preoperative Concurrent Chemoradiotherapy plus Radical Surgery for Advanced Squamous Cell Carcinoma of the Oral Cavity: An analysis of Long-term Results

    Oral Oncol 35: 597-606, 1999 Pg.No. 242

      

    The patients all had advanced, but potentially resectable, squamous cell carcinoma of the oral cavity, including, the soft palate. All had a tumor size of at least 30 mm; regional lymph node involvement was acceptable.

      

    All received concurrent cisplatin – or carboplatin-based chemotherapy with stimultaneous radiation therapy [target volume, 40
    Gy].

      

    At an average follow-up of 7 years, the patients were evaluated for late toxicity, locoregional control, distant metastases, second primary malignancies, are survival.

     

    Ten-year progression-free survival by histopathologic grade after preoperative chemoradiotherapy was 40% for patients in grade IIa, 89% for those in grade IIb, 100% for those in grade III, and 88% for those in grade IV.

      

    The association between histologic regression grade and survival persisted on long-term analysis.

      

    Long-term results support the use of preoperative concurrent chemoradiotherapy for patients with advanced squamous cell cancer of the oral cavity.

       


 

 



 

 

Speciality Spotlight

 

 

Malignant
   

  • Kirita T, Ohgi K, Shimooka H, et al [ Nara Med Univ, Japan]
    Preoperative Concurrent Chemoradiotherapy plus Radical Surgery for Advanced Squamous Cell Carcinoma of the Oral Cavity: An analysis of Long-term Results
    Oral Oncol 35: 597-606, 1999 Pg.No. 242
      
    The patients all had advanced, but potentially resectable, squamous cell carcinoma of the oral cavity, including, the soft palate. All had a tumor size of at least 30 mm; regional lymph node involvement was acceptable.
      
    All received concurrent cisplatin – or carboplatin-based chemotherapy with stimultaneous radiation therapy [target volume, 40 Gy].
      
    At an average follow-up of 7 years, the patients were evaluated for late toxicity, locoregional control, distant metastases, second primary malignancies, are survival.
     
    Ten-year progression-free survival by histopathologic grade after preoperative chemoradiotherapy was 40% for patients in grade IIa, 89% for those in grade IIb, 100% for those in grade III, and 88% for those in grade IV.
      
    The association between histologic regression grade and survival persisted on long-term analysis.
      
    Long-term results support the use of preoperative concurrent chemoradiotherapy for patients with advanced squamous cell cancer of the oral cavity.
       

 

 

 

By |2022-07-20T16:44:04+00:00July 20, 2022|Uncategorized|Comments Off on Malignant

About the Author: